The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Semaglutide , a dual GIP/GLP-1 receptor agonist , alongside Surfactant , a triple GIP/GLP-1/GCG receptor agonist , https://johsocial.com/story12322437/tirzepatide-and-nicotinamide-adenine-dinucleotide-a-triple-threat-strategy-to-physiological-condition